Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-world dupixent study tracks eczema improvement in 305 canadians

NCT ID NCT06099704

Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 305 Canadian adults and children (ages 6+) with moderate-to-severe eczema who were prescribed Dupixent as part of their routine care. Researchers measured how many patients achieved at least a 75% reduction in eczema severity after 6, 12, and 18 months. The goal was to see how well the treatment works in everyday practice, not just in controlled trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

305 people

The number who actually took part.

Started

Oct 2023

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Canadian msAD participants (ages 6+) who receive Dupixent for msAD according to the Canadian-country specific prescribing information (in accordance with the Canadian Dupixent Product Monograph)

Ages

6 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female, 6 years or older at baseline visit (Canada has received the country's regulatory approval for use of Dupixent treating msAD for these ages). * Participant is initiating dupilumab as part of routine clinical care through the Dupixent Patient Support Program (PSP) for the treatment of msAD, as per reimbursement criteria. Decision to treat with dupilumab must have been reached prior to and independently of recruitment in the study. * Have a physician's diagnosis of msAD. * Provided signed informed consent or parental/legally acceptable representative consent and/or participant assent. During the study, subjects will continue to receive maintenance therapies for their AD as clinically indicated and as per usual medical practice. * Participant or Parental representative able to understand English and/or Canadian French to complete study-related questionnaires. Exclusion Criteria: * Participants who have a contraindication to the drug according to the Canadian-specific prescribing information label. * Any condition that, in the opinion of the Investigator, may interfere with participant's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the participant from adequately completing the schedule of visits and assessments. * Participants currently participating in any interventional clinical trial which modifies participant care. * Prior use of Dupixent within 6 months of the baseline visit. * Participants not willing to sign the Informed Consent Form.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Moderate-to-severe atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Moderate-to-severe atopic dermatitis

Contacts and locations

Locations

  • Investigational Site Number : 1240002

    Ajax, Ontario, L1S 7K8, Canada

  • Investigational Site Number : 1240003

    Regina, Saskatchewan, S4V 1R9, Canada

  • Investigational Site Number : 1240005

    Richmond Hill, Ontario, L4E 4L6, Canada

  • Investigational Site Number : 1240006

    Pointe-Claire, Quebec, H9R 5M7, Canada

  • Investigational Site Number : 1240007

    Edmonton, Alberta, T5K 1X3, Canada

  • Investigational Site Number : 1240008

    Peterborough, Ontario, K9J5K2, Canada

  • Investigational Site Number : 1240009

    Edmonton, Alberta, T5J 3S9, Canada

  • Investigational Site Number : 1240010

    Surrey, British Columbia, V3R 6A7, Canada

  • Investigational Site Number : 1240011

    Etobicoke, Ontario, M8X 1Y9, Canada

  • Investigational Site Number : 1240012

    Montreal, Quebec, H3H 2R9, Canada

  • Investigational Site Number : 1240013

    Québec, G1W 4R4, Canada

  • Investigational Site Number : 1240014

    Toronto, Ontario, M5G 1X8, Canada

  • Investigational Site Number : 1240015

    Toronto, Ontario, M5G 1E2, Canada

  • Investigational Site Number : 1240016

    London, Ontario, N6A 5R9, Canada

  • Investigational Site Number : 1240017

    Montreal, Quebec, H3T 1C5, Canada

  • Investigational Site Number : 1240018

    Waterloo, Ontario, N2J 1C4, Canada

  • Investigational Site Number : 1240019

    Calgary, Alberta, T2J 7E1, Canada

  • Investigational Site Number : 1240020

    Halifax, Nova Scotia, B3H 4R2, Canada

  • Investigational Site Number : 1240021

    Calgary, Alberta, T3B 6A8, Canada

  • Investigational Site Number : 1240023

    Saint-Jean-sur-Richelieu, Quebec, J3A 1B5, Canada

  • Investigational Site Number : 1240024

    Barrie, Ontario, L4M 7G1, Canada

  • Investigational Site Number : 1240025

    Newmarket, Ontario, L3Y 5G8, Canada

  • Investigational Site Number : 1240026

    Fredericton, New Brunswick, E3B 1G9, Canada

  • Investigational Site Number : 1240027

    Saskatoon, Saskatchewan, S7K 2C1, Canada

  • Investigational Site Number : 1240028

    Nanaimo, British Columbia, V9V 1A3, Canada

  • Investigational Site Number : 1240029

    Winnipeg, Manitoba, R3M 3Z4, Canada

  • Investigational Site Number : 1240030

    Toronto, Ontario, M4E 1R7, Canada

  • Investigational Site Number : 1240031

    Cobourg, Ontario, K9A 0Z4, Canada

  • Investigational Site Number : 1240033

    Toronto, Ontario, M3B 0A7, Canada

  • Investigational Site Number : 1240034

    Whitby, Ontario, L1N 8M7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.